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The endocannabinoid system has emerged as a promising target for the treatment of numerous 
diseases, including cancer, neurodegenerative disorders, and metabolic syndromes. Thus far, two 
cannabinoid receptors, CB1 and CB2, have been discovered, which are found predominantly in 
the central nervous system (CB1) or the immune system (CB2), among other organs and tissues. 
CB1 receptor ligands have been shown to induce a complex pattern of intracellular effects. The 
binding of a ligand induces distinct conformational changes in the receptor, which will 
eventually translate into distinct intracellular signaling pathways through coupling to specific 
intracellular effector proteins. These proteins can mediate receptor desensitization, trafficking, or 
signaling. Ligand specificity and selectivity, complex cellular components, and the concomitant 
expression of other proteins (which either regulate the CB1 receptor or are regulated by the CB1 
receptor) will affect the therapeutic outcome of its targeting. With an increased interest in G 
protein-coupled receptors (GPCR) research, in-depth studies using mutations, biological assays, 
and spectroscopic techniques (such as NMR, EPR, MS, FRET, and X-ray crystallography), as 
well as computational modelling, have begun to reveal a set of concerted structural features in 
Class A GPCRs which relate to signaling pathways and the mechanisms of ligand-induced 
activation, deactivation, or activity modulation. This review will focus on the structural features 
of the CB1 receptor, mutations known to bias its signaling, and reported studies of CB1 receptor 
ligands to control its specific signaling. 
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Abstract: The endocannabinoid system has emerged as a promising target for the treatment of
numerous diseases, including cancer, neurodegenerative disorders, and metabolic syndromes.
Thus far, two cannabinoid receptors, CB1 and CB2, have been discovered, which are found
predominantly in the central nervous system (CB1) or the immune system (CB2), among other organs
and tissues. CB1 receptor ligands have been shown to induce a complex pattern of intracellular effects.
The binding of a ligand induces distinct conformational changes in the receptor, which will eventually
translate into distinct intracellular signaling pathways through coupling to specific intracellular
effector proteins. These proteins can mediate receptor desensitization, trafficking, or signaling.
Ligand specificity and selectivity, complex cellular components, and the concomitant expression of
other proteins (which either regulate the CB1 receptor or are regulated by the CB1 receptor) will affect
the therapeutic outcome of its targeting. With an increased interest in G protein-coupled receptors
(GPCR) research, in-depth studies using mutations, biological assays, and spectroscopic techniques
(such as NMR, EPR, MS, FRET, and X-ray crystallography), as well as computational modelling,
have begun to reveal a set of concerted structural features in Class A GPCRs which relate to signaling
pathways and the mechanisms of ligand-induced activation, deactivation, or activity modulation.
This review will focus on the structural features of the CB1 receptor, mutations known to bias its
signaling, and reported studies of CB1 receptor ligands to control its specific signaling.
Keywords: CB1 receptor; biased signaling; functional selectivity; cannabinoids
1. Introduction
The CB1 receptor was first determined and characterized as the receptor protein for ∆9-THC,
the major psychoactive constituent in Cannabis Sativa (Marijuana), from rat brain preparations in
1988 [1]. Cloning of a CB1 receptor from a rat cerebral cortex [2], followed by the cloning of a human
CB1 receptor from the brain stem [3], has prompted ongoing research in the cannabinoid field. The
CB1 receptor represents a promising target for the development of novel therapeutics for the treatment
of different pathologies, including metabolic syndromes and neurodegenerative diseases, as well as the
symptomatic relief of neuropathic pain in patients with multiple sclerosis and spinal cord injuries [4,5].
This broad spectrum of possible therapeutic applications by targeting the CB1 receptor originates
from its high expression levels in the central nervous system (CNS), being located primarily at the
presynaptic terminals of central and peripheral neurons, and from its neuro-modulatory action [6–8].
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For example, low expression levels and desensitization of the CB1 receptor have been associated with
early (pre-symptomatic) stages of Huntington’s disease (HD) and Parkinson’s disease (PD) [9,10].
Activation of CB1 induces a wide spectrum of intracellular signaling cascades through its coupling
to different intracellular effector proteins, including G-proteins and β-arrestins [11]. Each of these
signaling cascades results in a unique pharmacological response, which could be exploited to develop
novel therapeutics for the treatment of particular disease states. A recent study demonstrated
that the endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (AEA) are promising
candidates for targeting HD, compared with the classical cannabinoids (CP55,940 and ∆9-THC) [12,13].
A molecular-level understanding of the structural determinants of biased signaling at the CB1 receptor
should contribute to the development of novel therapeutics able to activate diverse signaling paradigms.
2. CB1 Signaling
Activation of the CB1 receptor inhibits forskolin-stimulated adenylyl cyclase by coupling
to the pertussis toxin (PTX)-sensitive G-protein (Gαi/o) and increases the phosphorylation of
extracellular signal-regulated kinase 1/2 (pERK1/2) through G-protein dependent and β-arrestin1
dependent pathways [11,14]. The Gαi/o mediated decrease in cAMP upon CB1 activation activates
G-protein-coupled inwardly-rectifying potassium channels (GIRKs) and inhibits N-type and P/Q
type voltage-gated calcium channels, resulting in an inhibition of pre-synaptic neurotransmitter
release. Stimulation of CB1 also leads to phosphorylation and activation of mitogen-activated
protein kinases (MAPK), such as p38 MAPK and c-Jun N-terminal kinase, which can regulate nuclear
transcription [6,15,16]. While CB1 couples mainly through the Gαi/o type G-protein, coupling to other
G-protein types under special circumstances has been also reported, such as coupling to Gαs [17–21],
and Gαq/11 [22].
Phosphorylation and Subsequent β-Arrestin Recruitment
In the canonical GPCR signaling pathway, G-protein-coupled receptor kinases (GRKs)
phosphorylate serine and/or threonine residues on the intracellular (IC) domain of agonist-activated
receptors, mainly at the C-terminus and/or the third IC loop [23]. It has also been reported that
individual GRKs elicit distinct phosphorylation patterns (barcodes), resulting in different downstream
signaling [24]. β-arrestin recruitment to the phosphorylated receptor depends on the phosphorylation
pattern and redirects the G-protein-dependent signaling state of the receptor to other possible states,
depending on the type of β-arrestin being recruited. The two non-visual arrestins—β-arrestin1 and
β-arrestin2—are expressed ubiquitously in mammalian tissues and mediate GPCR desensitization,
endocytosis, ubiquitination, or G-protein independent signaling [25,26]. β-arrestin recruitment to
the phosphorylated receptor may sterically inhibit G-protein coupling to the activated receptor,
thus quenching the G-protein signal and reducing the receptor’s response to repeated stimulation,
known as receptor desensitization [27–29]. On the other hand,β-arrestins may act as scaffolding proteins,
in which they can mediate clathrin-mediated receptor endocytosis by binding to β(2)-adaptin and
clathrin, or they can mediate G-protein independent intracellular signaling pathways by scaffolding
mitogen-activated-protein-kinase (MAPK) signaling modules, including the ERK1/2, p38MAPK,
and c-Jun N-terminal kinases, as well as scaffolding the Src family tyrosine kinases and protein
phosphatases [23,26,30–33]. In addition, non-canonical G-protein independent β-arrestin recruitment
to GPCRs has been reported [25,34,35]. GRK5 and GRK6 have been reported to be able to phosphorylate
inactive receptors; this fact may explain the ability of β-arrestins to recruit GPCRs in a G-protein
independent way [36]. For example, Org-27569 has been reported to induce a G-protein-independent
β-arresin1-dependent pERK1/2 signal in HEK293 cells expressing a CB1 receptor, where the signal was
shown to be PTX-insensitive [11].
In vitro studies on the effects of GRKs and arrestins on CB1 receptor signaling, desensitization,
and internalization will be discussed in later sections. On the other hand, in vivo studies using
β-arrestin1 and β-arrestin2 knockout mice demonstrated that the β-arrestins regulate cannabinoid
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sensitivity and activity in an agonist-selective (as well as in a region-specific) manner [28,37–39].
For example, repeated administration of ∆9-THC to mice resulted in the differential upregulation of
GRK2, GRK4, β-arrestin1, and β-arrestin2 in different regions of the CNS, while GRK5 and GRK6 levels
in the same study were not affected [40]. On the other hand, deletion of β-arrestin2 attenuated tolerance
to ∆9-THC mediated antinociception, and reduced ∆9-THC-induced desensitization in the cerebellum,
caudal periaqueductal gray, and spinal cord; yet, it increased desensitization in the hypothalamus,
cortex, globus pallidus, and substantia nigra [37]. In a different study, deletion of β-arrestin2 selectively
enhanced the antinociceptive and temperature-depressive efficacy of ∆9-THC without affecting the
efficacy of other ligands, such as CP55,940, methanandamide, JWH-073, and O-1812 [39]. On the other
hand, the deletion of β-arrestin1 had no effect on the efficacy or tolerance development (in tail-flick
and rectal temperature assays) of ∆9-THC. β-arrestin1 deletion, on the other hand, diminished the
effects of CP55,940 in both assays, despite an increase in CP55,940-induced [35S]GTPγS binding [38].
This may indicate that the antinociceptive and the temperature-depressive effects of CP55,940 are not
G-protein dependent.
3. Structural Determinant of G-Protein Coupling versus β-Arrestin Coupling at CB1: Insights
from Mutation Studies and Crystal Structures
CB1 is a member of the Class A GPCRs and shares their general topological features;
seven transmembrane helices (TMH) joined by extracellular (EC) and intracellular (IC) loops of
varied lengths, with an extracellularly-extending N terminus, as well as an intracellular C terminus
which begins with a short helical segment (Hx8), oriented parallel to the cell membrane. The binding
site for endogenous ligands is generally formed by the EC core within the TMH bundle and may extend
to the EC loops (referred to as the orthosteric binding site) (Figure 1). Similar to other Class A GPCRs,
which are activated by lipid-derived endogenous ligands [41–43], the crystal structures of CB1 suggest
a transmembrane portal through which an antagonist may diffuse from the lipid bilayer towards the
binding site [44,45]. Ligands may also bind to distinct (allosteric) binding sites of the receptor [46–48].
Differential coupling of the receptor to G-proteins or β-arrestins in a biased or un-biased fashion
is determined by the conformation of the receptor at the IC domain (including the cytoplasmic
transmembrane domain, the IC loops, and the C-terminus). Binding of an agonist to the receptor
induces a set of ligand-specific conformational changes in the binding site, which are translated into
distinct conformational changes in the IC domain. Such changes confer a best fitting between the
receptor and specific IC effector protein(s) and result in unique intracellular signals and pharmacological
responses. In general, the activation of class A GPCRs results in an opening at the IC domain. Available
active state crystal structures reveal a set of concerted rearrangements in conserved motifs within this
class of receptors, resulting in an opening at the TMH 3/5/6 region allowing the G-protein C-terminal
α5 helical domain to form interactions with the receptor [49–55]. However, few features are yet known
that describe the conformational changes associated with G-protein-independent β-arrestin coupling
to the receptor. The published crystal structure of the 5-HT2B receptor bound to β-arrestin biased
agonist (LSD), shows a unique rotameric state of conserved tyrosine in TMH7 (Y7.53) adopting a trans
χ1 dihedral, compared to the g+ χ1 dihedral commonly seen in the active state crystal structures of
GPCRs bound to non-selective agonists [56]. Biophysical studies on the arginine–vasopressin receptor
and β2AR have shown a movement of TMH7 in receptors treated with β-arrestin biased ligands,
compared to a movement of TMH6 in receptors treated with G-protein activating ligands [57,58].
In addition to their ability to bind GPCRs in the core-conformation (the finger-loop region
of arrestins interact with the cytoplasmic core of the receptor), arrestins have also been reported
to bind to the receptor in the tail-conformation; where the arrestin is bound to the C-terminus of
the receptor only [59]. By interacting in the tail conformation, arrestins preserve their ability to
mediate G-protein independent signaling and receptor internalization, but not desensitization [59].
Interestingly, GPCR–G-protein–β-arrestin megaplexes have been reported, in which arrestin is engaged
to the GPCR in the tail conformation, allowing concomitant binding of G-protein to the receptor,
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these megaplexes explain the ability of some GPCRs, including CB1, to activate G-proteins from
internalized compartments [60–62].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 4 of 24 
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Figure 1. Human CB1 Helix net. (I1–I3 for the intracellular (IC) loops, E1–E3 for the extracellular (EC)
loops). The most conserved amino acid residue in each helix in red. Purple highlights for putative
phosphorylation sites on the C-terminus of the receptor. Blue highlights for negatively-charged residues
in the C-terminus. Other residues discussed are highlighted in orange; in order, they are: F3.36, L3.43,
T3.46, Y3.49, D3.51, W6.48, L341(6.33), A342(6.34), D6.30, and Y7.53.
At CB1, an in-situ reconstitution technique was used to directly measure G-protein activation [63],
and a Plasmon Wave-guide Resonance (PWR) spectroscopy study [64] demonstrated that different
agonists induce different conformational changes in CB1, resulting in the preferential activation of
different G-proteins. Fay and Farrens demonstrated differences in the structure of CB1 stabilized by
ORG27569 (a biased β-arrestin1 allosteric ligand [65]) from that stabilized by CP55,940 (a non-biased
orthosteric agonist [11,17]); specifically, TMH6 movement was blocked, while TMH7/Hx8 movement
was enhanced, upon ORG27569 binding [66]. In addition, a recent study demonstrated the different
kinetics of Ca2+ mobilization after treatment with WIN55,212-2 or CP55,940, suggestive of ligand-specific
binding or activation kinetics [67]. Structural determinants of biased signaling at CB1 will be discussed
in following sections; those at the cytoplasmic transmembrane domain of the receptor, and the structural
determinant at the C-terminus and IC loops.
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3.1. Structural Determinant of Biased Signaling in the Cytoplasmic Transmembrane Domain of the Receptor
Despite the tremendous variation in chemical structures of agonists that bind and activate Class A
GPCRs, GPCRs share common molecular activation mechanisms. This is due to a set of amino acid
residues which are highly conserved at the majority of non-olfactory members (ligand-modulated
receptors) of this class [68]. These residues are thought to act as molecular switches that undergo
concerted conformational changes upon ligand binding and determine the conformation of the receptor
at the IC domain. Conserved amino acid residues include the following motifs: NxLV in TMH1,
LAxAD in TMH2, the D/ERY motif in TMH3, FxxCWxP in TMH6, and the NSxxNPxxY motif in TMH7.
The role of conserved amino acid residues in Class A GPCR signaling, including the CB1 receptor,
have been investigated through mutation. However, their exact role in biased signaling is still not well
understood, because most of these mutations were evaluated for their canonical G-protein signaling
efficacy only, while their efficacy in β-arrestin signaling is yet emerging in the literature. In addition,
the signaling properties of those mutants could also be ligand-specific.
The G-protein coupling active state crystal structure of CB1 shows, in agreement with other
Class A GPCRs, a counterclockwise rotation (EC view) of the IC domain of TMH6 and flexing in the
TMH6 CWxP hinge region, resulting in the outward movement of the IC end of TMH6; away from
TMH3. This movement will break the ionic interaction between R3.50 and D6.30 at the IC ends of
TMH3/6 [52–54,69]. Flexing in the CWxP motif is produced by ligand binding, which alters the χ1
dihedral angles of the “toggle switch” residues. For CB1, these are F3.36 in TMH3 and a tryptophan
residue (W6.48) which is part of the CWxP motif [69–72]. The F3.36A CB1 mutation resulted in
increased basal [35S]GTPγS binding of the receptor. The authors concluded that F3.36 stabilizes an
inactive state of the receptor by stabilizing W6.48 in its inactive rotameric state (χ1 = g+) [70,72],
which was confirmed, subsequently, by the CB1 crystal structures [44,45,69] (see Supplementary
Materials cb1-sequence-alignment.xlsx for sequence numbering).
Conformational changes in TMH7 and TMH3 have also been shown to occur during G-protein
mediated signaling. In the inactive state, TMH7 is packed against TMH3, which is engaged with a
conserved change in the χ2 dihedral of Y7.53 by −60◦, facilitating its interaction with R3.50 in its active
rotameric state (Figure S1). Interestingly, a site-directed fluorescence labeling (SDFL) study using a
minimal cysteine CB1 receptor has shown that CP55,940-induced changes in bimane fluorescence
occur faster in the Hx8-attached probe (at L7.60), compared to that attached to TMH6 (at A6.34).
This may suggest that the inward movement of TMH7/Hx8 precedes the outward movement of TMH6
in G-protein signaling [66]. In addition, the packing of TMH7 against TMH3 is enhanced by a rotational
movement of TMH3 towards TMH2, which relieves a steric clash that would occur between Y7.53 and
a highly conserved non-polar amino acid residue (L3.43) upon activation (Figure S2). In agreement
with this, a CB1 L3.43A mutant displayed higher constitutive activity, demonstrated by a higher
basal-specific GTPγS binding, compared to the WT receptor [20,73].
On the other hand, the CB1 receptor has an atypically polar amino acid residue (T3.46),
compared with a conserved non-polar (I/L/M/V) residue in most (95%) Class A GPCRs. This residue is
located one turn extracellular to the DRY motif. A T3.46I mutant receptor expressed in HEK293 cells
exhibited increased constitutive (GTPγS binding) activity and internalization of the receptor, while the
T3.46A mutant exhibited lower constitutive activity and had an increased thermal stability, suggestive
of a shift towards the inactive state [73–75].
The most conserved residue in TMH3 across Class A GPCRs is R3.50. This residue is part of the
E/DRY motif. It stabilizes the inactive state of the receptor by forming an interaction with a (usually
acidic) residue on TMH6 (D/E6.30); this interaction is broken upon activation of the receptor (in the
G-coupling active state) and R3.50 adopts a unique rotameric state, where it forms a triad interaction
with both Y7.53 and Y5.58. Despite forming key interactions in both states, the mutation of this residue
results generally in reduced basal- and agonist-induced signaling in different receptors, suggestive
of a role of this residue in stabilizing the active state of the receptor and/or being involved in the
GPCR/G-protein interaction and activation [76,77]. On the other hand, a non-conserved mutation of
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E/D3.49, which stabilizes the inactive state of the receptor by forming an ionic interaction with R3.50 in
the inactive state, resulted unexpectedly in either an enhancement or inhibition of the constitutive
activity of different receptors [76,77]. Gyombolai et al. [78] examined the effects of single, double,
and triple mutants of the DRY motif in the CB1 receptor, expressed in CHO cells and treated with 2-AG
or WIN55,212-2. An R3.50A CB1 mutant displayed a 20% decrease in its ability to recruit Go-proteins
without affecting the basal recruitment to the receptor or the EC50 values of 2-AG or WIN55,212-2;
it, additionally, displayed enhanced basal β-arrestin2 recruitment. The double mutant AAY, on the
other hand, reduced Go protein recruitment, with a complete loss of ability to inhibit forskolin-induced
cAMP accumulation, and displayed an increase in both basal and maximum β-arrestin1/2 recruitment,
suggestive of its β-arrestin biased signaling properties [78]. A similar mutant of the angiotensin-1A
receptor has also been reported to be β-arrestin biased [79]. In contrast, a CB1 DAA double mutant
showed impaired recruitment of Go-proteins and impaired ability to inhibit forskolin-stimulated
cAMP but resulted in a complete loss of β-arrestin1/2 recruitment. An impairment in recruitment
of β-arrestins was also characteristic of the single DRA mutant with increased basal Go-protein
recruitment [78]. Data suggested a role of Y3.51 in stabilizing a β-arrestin-coupling active state of the
receptor, possibly through stabilization of the IC2 loop of the receptor. It is worth mentioning, however,
that the same study reported that, for the β-arrestin-biased double mutant (AAY), the pERK signal
was no different from the WT receptor; despite the robust increase in β-arrestin1/2 recruitment [78].
This signals the need to differentiate between the ability of the receptor to recruit any of the intracellular
effector proteins versus it ability to activate and signal through those proteins.
The most conserved residue in TMH2 (D2.50) has been also explored in different studies.
A neutralization mutant of this residue (D2.50N) has been reported to inhibit receptor internalization in
ATt20 and HEK293 cells expressing the mutant, without affecting CP55,940- and WIN55,212-2-induced
pERK1/2 signals [29,80]. The mutant blocked CP55,940- and WIN55,212-2-induced potentiation of
inwardly-rectifying potassium channel (KIR) currents evaluated in ATt20 cells expressing D2.50N and
in oocytes co-expressing D2.50N/GIRK1/4 [80,81]. The same mutation did not affect the agonist-induced
inhibition of Ca2+ currents [80,82] despite the fact that the modulation of both Ca2+ and K+ currents are
G-protein-dependent. On the other hand, inhibition of forskolin-stimulated cAMP accumulation has
been found to be attenuated in HEK293 cells expressing a mutant receptor [83]; yet had been reported
as not affected in another study, where D2.50N was expressed in ATt20 cells [80].
3.2. Structural Determinants at the C-Terminus and the IC Loops
The C-terminus in CB1 contains multiple serine, threonine, aspartate, and glutamate residues.
According to the recently-proposed phosphorylation code, a maximum separation of two amino
acid residues between phosphorylated or negatively charged residues is suggested for high-affinity
binding to arrestin [84,85]. The membrane-proximal segment of the C-terminus which contains the
sequence D423-NSMGDS-D430 (hCB1 numbering), and the membrane distal segment which contains
T460-MSVSTDTSA-E470, are two possible β-arrestin interaction sites at the C-terminus of the CB1
receptor. The central segment, on the other hand, contains phosphorylation sites that are separated by
more than two amino acid residues, which implies low (or no) interaction of the arrestins with the CB1
receptor at this region (Figure 2).
Crystal structures of the CB1 receptor, in its active and inactive states, resolved only a short segment
of the C-terminus, Hx8 [44,45,69]. Efforts to determine the structure of the complete C-terminus revealed
a possible variation in the structure upon phosphorylation; an NMR structure of the un-phosphorylated
full-length C-terminus (R400–L472) in dodecylphosphocholine revealed an additional amphipathic
helical structure (A440–M461) named H9 [86]. On the other hand, two helical segments, extending from
L423 to L433 and separated by a glycine residue (G428), were observed for the diphosphorylated peptide
segment (T419–N439, phosphorylated at S426/S430) upon binding to β-arrestin1 [87]. In addition,
a solution NMR experiment for a pentaphosphorylated peptide segment (T454–L473 phosphorylated
at T454, S463, S465, T468, S469) in a complex with β-arrestin1 revealed a helical segment at D467–E471,
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with no signs of interaction between the un-phosphorylated segment and β-arrestin1 (determined
using isothermal titration calorimetry) [88].
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3.2.1. G-Protein Interaction with the C-Terminus and IC loops
Different studies demonstrated the involvement of proximal C-terminus (R401–E417), and both
the second and third IC loops, in the binding of G-proteins to CB1 [89–93]. Truncation of the distal
C-terminus (CB1–417) increases the constitutive activity and G-protein sequestration of the receptor [82],
which might be attributed to reduced β-arrestin recruitment to the receptor. An inversion mutant
at the third IC loop (L341A–A342L mutation) attenuates the association with Gi-proteins, which has
been attributed to a loss of helicity in that loop [94]; this mutant resulted in an increase in basal- and
agonist-induced cAMP and has been proposed to couple to Gαs [21,95]. However, the increase in
cAMP upon CB1 stimulation has been attributed, in a later study at Howlett’s Lab, to reduced Gαi/o
function [95].
3.2.2. β-Arrestin2 Recruitment to Phosphorylated C-Terminus Proximal to the Transmembrane
Domain Results in Receptor Desensitization
As discussed earlier, receptor desensitization results from β-arrestin binding to the core of the
receptor, which will sterically inhibit the binding of G-proteins to the receptor. The following studies
confirm the ability of β-arrestin2 to desensitize the receptor when bound to the phosphorylated
C-terminus proximal to the transmembrane domain of CB1.
Mackie’s lab demonstrated the role of GRK3 and β-arrestin2 in CB1 receptor desensitization
using Xenopus oocytes transfected with rat CB1. Attenuation of G-protein dependent Kir current,
during an 8 min exposure to WIN55,212-2, required co-expression of both GRK3 and β-arrestin2.
In the same study, truncation mutants of the whole C-terminus (∆418), or (∆418–439) did not result in
receptor desensitization, while truncation at 439 and at 460 resulted in WIN55,212-2-induced receptor
desensitization. In addition, S426A or S430A mutations significantly attenuated desensitization,
while they had no effect on the internalization of the receptor evaluated in AtT20 cells treated
with WIN55,212-2 [27]. A subsequent study in HEK293 cells, on the other hand, showed that the
S426A/S430A mutant recruits β-arrestin2 to a similar extent in the WT receptor, suggesting the ability
of β-arrestin2 to be recruited to the distal C-terminus of the receptor [29]. It is worth-mentioning,
here, that β-arrestin2 mRNA has been reported to be expressed in both HEK293 and AtT20 cell
lines, while β-arrestin1 mRNA was only expressed in HEK293 cells [96]. Moreover, cultured autaptic
hippocampal neurons from mutated (S426A/S430A) mice showed enhanced WIN55,212-2-mediated
depolarization-induced suppression of excitation (DSE) and reduced agonist-mediated desensitization
of DSE, which has been translated, in vivo, into mutant mice that were more sensitive to the
antinociception and hypothermic effects induced by ∆9-THC and endocannabinoids, delayed tolerance,
and increased ∆9-THC-dependence [97]. In a different study, treatment with WIN55,212-2 resulted in
desensitization of the ∆419–460 rCB1 receptor transfected into CB1 knockout autaptic hippocampal
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neurons; the distal segment of the C-terminus (including putative phosphorylation sites at T461–S469)
was, thus, directly attached to the transmembrane bundle [98].
An immunoprecipitation study from Howlett’s lab, using cultured N18TG2 neuroblastoma cells,
demonstrated that a synthetic phosphorylated proximal C-terminal peptide segment (T419–H436
phosphorylated at S426/S430) and both phosphorylated and non-phosphorylated distal C-terminal
peptide segments (V460–L473 phosphorylation at T468) competed for the association of β-arrestin2
with the CB1 receptor [99].
Results from all the above studies suggest that β-arrestin2 can be recruited to the phosphorylated
proximal C-terminus in the WT receptor, resulting in receptor desensitization, while it can still be
recruited to the distal region of the C-terminus in the absence of phosphorylation at S426/S430, resulting
in receptor internalization but not desensitization, as will be discussed below (Figure 3).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 24 
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Figure 3. Canonical CB1 receptor signaling and β-arrestin2 interaction with the receptor. (A) Inactive
state of the receptor with closed IC domain. (B) Agonist binding activates the receptor with opening
at IC domain, mainly due to the TMH6 conformational change followed by G-protein coupling.
(C) Phosphorylation of proximal (S425, S429) and distal (possibly at T460–S468) phosphorylation sites,
by GRK3 and GRKs5/6, respectively. (D) β-arrestin2 binding to the C-terminus starts with an interaction
with the distal phosphorylated C-terminus, which can mediate receptor internalization; followed by (E)
possible conformational change at the IC domain of the receptor and the arrestin interacts with the
proximal phosphorylated C-terminus, resulting in receptor desensitization.
3.2.3. β-Arrestin2 Recruitment to Phosphorylated C-Terminus Distal to the Transmembrane Domain
Results in Receptor Internaliza ion
While the phosphorylation pattern at the proximal C-terminus seems to be important for receptor
desensit zation, phosphorylation at he distal C-terminus has bee proposed to be i lic ted in
inter alization [100]. β-ar estin2 has been etermined to be essential for ag ni t-induced
ntern lization of the receptor [65,101].
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To determine critical phosphorylation site residues required for internalization, Mackie’s lab
introduced different mutations to the distal C-terminus of the CB1 receptor, expressed in HEK293
cells. T461A/S463A, S465A/T466A, and T468A/S469A double mutants showed a similar extent of
internalization and an efficient, but slower, rate of β-arrestin2 recruitment to the plasma membrane
compared to the WT, upon treatment with CP55,940. However, mutating four or all six putative
phosphorylation sites (T461A–T466A and T461A–S469A) significantly attenuated CP55,940-induced
receptor internalization, and did not show translocation of β-arrestin2 to the membrane [100].
Interestingly, the same study reported that a CB1 receptor lacking the last 14 amino acid residues
(V460Z) and expressed in HEK293 cells internalized to the same extent as the WT receptor and could
recruit β-arrestin2 to the membrane [100]. A possible scenario of the interaction of β-arrestin2 with
the C-terminus of the receptor could be proposed, based on those results; β-arrestin2 binding to the
C-terminus of the WT receptor is initiated with an interaction with the distal phosphorylated C-terminus,
followed by interaction with the proximal phosphorylated C-terminus region of the receptor. It can
also suggest that the distal C-terminus has a specific (and not random) location, with respect to
the proximal C-terminus, and that the binding of β-arrestin2 to the proximal C-terminus can also
induce receptor internalization. Thus, β-arrestin2 could recruit to double mutants (T461A/S463A,
S465A/T466A, and T468A/S469A) inducing internalization due to the availability of phosphorylation
sites at the distal C-terminus; but, it could not recruit to the receptor with four and six mutations
(T461A–T466A and T461A–S469A) due to lack of phosphorylation sites at those residues and because
the non-phosphorylated distal C-terminus occludes other phosphorylation sites at the proximal
C-terminus. However, truncation of the distal C-terminus (V460Z) permitted direct interaction of
β-arrestin2 with the proximal phosphorylated C-terminus, which resulted in receptor internalization
(see Figure 3).
3.2.4. β-Arrestin1 Recruitment to the Receptor Results in G-Protein Independent Signal
Phosphorylated proximal and distal peptide segments have been shown to bind β-arrestin1,
as discussed earlier (see Section 3.2). However, an immunoprecipitation study from Howlett’s lab,
using cultured N18TG2 neuroblastoma cells, suggested that β-arrestin1 interacts only with the proximal
C-terminus (T419–H436) phosphorylated at S426/S430, and with the distal C-terminus (V460–L473)
phosphorylated at T468. They also reported the inability of a non-phosphorylated proximal peptide
segment to compete with β-arrestin1 for the association with CB1 [102]. On the other hand, a recent
study demonstrated significantly higher recruitment of β-arrestin1 to CB1 S426A/S430A, compared to
the WT receptor expressed in HEK293 cells. The same study found a weaker recruitment of β-arrestin2
to the CB1 S426A/S430A mutant, compared to the WT receptor 5 min after treatment with WIN55,212-2.
The mutant also resulted in an interesting shift in the functional selectivity of agonists (WIN55,212-2
and 2AG) towards inducing a biased β-arrestin1-dependent pERK1/2 signal in the mutant receptor [14].
Such paradoxical results from different labs could be due to the expression of CRIP1a in N18TG2 cells,
but not in HEK293 cells [103]. CRIP1a competes with arrestins for binding to a non-phosphorylated
C-terminus, which explains the inability of the non-phosphorylated proximal peptide segment to
recruit β-arrestin1 for its association with CB1 in N18TG2 cells [102]. A G-protein-independent
β-arrestin1 pERK1/2 signal has also been reported for ORG27569, as will be discussed in Section 4.3.2.
3.2.5. Recruitment of β-Arrestins to the C-Terminus Can be Altered in the Presence of Other
Regulatory Proteins
Expression of regulatory proteins that bind to the C-terminus of the CB1 receptor may alter
agonist-dependent/independent arrestin recruitment to the CB1 receptor. The cannabinoid receptor
interacting protein 1a (CRIP1a) has been demonstrated to interact mainly with non-phosphorylated
C-terminus of the CB1 receptor [102]. CRIP1a is a 164 amino acid residue protein with a predicted
palmitoylation site but no transmembrane domain, which has high expression in certain brain
regions, including the cerebral cortex, cerebellum, hippocampus, hypothalamus, and caudate nucleus.
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In vivo co-expression has been determined using a co-immunoprecipitation technique from rat brain
homogenates [103]. Furthermore, CRIP1a colocalization with the CB1 receptor at presynaptic termini
was also confirmed, using immune-histochemical studies in transgenic mice cerebellum [104]. CRIP1a
has been reported to attenuate agonist-induced CB1 receptor internalization [104], and modulate CB1
mediated activation of G-proteins in a subtype selective manner [102]. CRIP1a binds preferentially
to the non-phosphorylated C-terminus [99]. Its competition with arrestins for binding to the CB1
C-terminus has been proposed to explain the inability of a truncation mutant (V460Z), expressed
in AtT20 cells, to internalize, despite its ability to internalize in HEK2093 cells [100,105]. Lack of
β-arrestin1 expression in AtT20 cells should also be considered when comparing results from HEK293
cells [96]. In addition, V460Z or CB1 T461A–S469A transfected into CB1 knockout autaptic hippocampal
neurons did not desensitize following WIN55,212-2 or 2-AG treatment, despite the availability of
proximal phosphorylation sites in the mutated receptors [98].
In addition to CRIP1a, Src homology 3-domain growth factor receptor-bound 2-like (endophilin)
interacting protein 1 (SGIP1) is an 828 amino acid residue protein with a N-terminal lipid-binding
domain. SGIP1 has been shown to interact with the CB1 receptor C-terminus and to inhibit
clathrin-mediated endocytosis of the CB1 receptor. It has also been demonstrated to enhance CB1
receptor association with β-arrestin2, but not with β-arrestin1, and to lower WIN55,212-2-induced
PTX-sensitive ERK1/2 phosphorylation, while not affecting CB1 receptor mediated Gαi/o/q
activation [106]. In addition, SGIP1 has been demonstrated to co-localize at presynaptic termini
with the CB1 receptor in cultured cortical neurons, which may explain neuronal compartment-selective
endocytosis in which rapid CB1 receptor internalization is observed in neuronal soma, while resistance
to endocytosis is observed in presynaptic termini [32,106].
3.2.6. Phosphorylation of the C-Terminus
As discussed earlier, co-expression of GRK3 and β-arrestin2 in oocytes has been reported to
be essential for WT CB1 receptor desensitization [27]. Inhibition of GRK2 in N18TG2 cells did
not significantly affect CP55,940-induced internalization of the CB1 receptor [99]. In another study,
knocking down of GRK3 or GRK2/3 in HEK293 cells expressing rat CB1 receptors significantly increased
the pERK1/2 signal 15 min after WIN55,212-2 treatment, while knocking down GRK3 or GRK2/3 had no
effect on a CB1 S426A/S430A mutant receptor pERK1/2 signal [14]. As the 15 min WIN55,212-2-induced
pERK1/2 signal was determined to be G-protein dependent in the WT receptor [14], it can be concluded
that knocking down GRK3 (which phosphorylates proximal phosphorylation sites—specifically at
S426 and S430—in the C-terminus) reduces desensitization and internalization of the receptor, resulting
in a sustained G-protein dependent pERK1/2 signal in the WT receptor.
On the other hand, GRK4„ GRK5, or GRK6 knock-down resulted in a significantly lower pERK1/2
signal in a CB1 S426A/S430A mutant, but not in the WT receptor after treatment with WIN55,212-2 [14].
The WIN55,212-2-induced pERK1/2 signal has been determined to be β-arrestin1-dependent in the
S426A/S430A mutant receptor [14], and β-arrestin1 mediated signaling through the CB1 receptor has
been reported, previously, to be from endocytic pits [11]. If GRK4, GRK5, and GRK6 were involved in
the phosphorylation of distal phosphorylation sites which are essential for receptor internalization,
knocking down those GRKs may have reduced the internalization of the mutant receptor into
endocytic pits, resulting in a lower β-arrestin1 mediated pERK1/2 signal in the S426A/S430A mutant.
In cultured smooth muscle cells, GRK5 (but not GRK2) has also been reported to be essential for
the phosphorylation of CB1 after a 15 min treatment with 1 µM AEA, resulting in CB1 receptor
internalization and PTX-insensitive β-arrestin1/2-dependent ERK1/2 and Src kinase activation [107].
Other than GRKs, the CB1 receptor IC3 loop has been reported to be phosphorylated at S317 by
PKC in AtT20 cells transfected with rat CB1 receptor. Phosphorylation at S317 has been shown to
attenuate CB1 mediated activation of Kir currents [108].
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4. CB1 Biased Ligands
The pharmacology of numerous CB1 orthosteric and allosteric ligands has been deeply investigated
in different in vitro and in vivo models [109,110]. Research into their possible functional selectivity
has increased recently, due to the emergence of biased signaling as a novel potential therapeutic
approach. CB1 ligands of endogenous, phytogenic, and synthetic nature have been reported to elicit
biased cellular responses, as observed by using diverse functional endpoints. In this section, we will
summarize and classify the CB1 biased ligands identified so far, attending to their chemical structure.
4.1. Endocannabinoids
Diverse endogenous cannabinoids, including the well-known lipids 2-arachidonoylglycerol (2-AG)
and N-arachidonoylethanolamine (ananadamide, AEA) (Figure 4), have been reported to exhibit a CB1
biased signaling profile in specific cellular models. For instance, as described by Laprairie et al., 2-AG
and AEA displayed a functional selectivity in in vitro models of medium spiny projection neurons
expressing wild-type (STHdhQ7/Q7) or mutant huntingtin protein (STHdhQ111/Q111) and using the
Black and Leff operational model to quantify signaling bias [13,17]. According to these authors, 2-AG
elicited signaling bias toward Gαi/o, compared to β-arrestin1 and Gαq [17], while another report
showed that, in rat hippocampal neurons, 2-AG mediates autaptic long-term potentiation through
activation of CB1 Gαq [111]. These results indicate that the biased signaling of 2-AG at CB1 might be
cell-type dependent. Additional investigations exhibited that this endogenous CB1 agonist is more
efficacious at recruiting β-arrestin1 than β-arrestin2 in CB1-HEK293 cells [14]. These authors observed
that 2-AG mediated CB1 downstream signaling by G-proteins up to 5 min after incubation, after which
it switched to β-arrestin-mediated signaling mechanisms.
It is also worth mentioning that, in a study carried out by Khajehali et al., in which they investigated
the effects of CB1 ligands in cAMP inhibition and pERK1/2 assays in CHO-CB1 cells, 2-AG did not
show a specific preference for any of those signaling outcomes [35].
Similar to 2-AG, Laprairie et al. reported that, in STHdh cells, AEA signaling was biased toward
Gβγ, compared to Gαi/o, and Gαi/o-biased, compared to β-arrestin1 and Gαq [13,17]. However,
in contrast to 2-AG, AEA exhibited a clear preference toward cAMP inhibition, compared to pERK1/2,
in the previously-mentioned experiments carried out by Khajehali et al. [35].
The synthetic chiral analog of AEA, (R-(+)-methanandamide, mAEA, Figure 4), displayed
functional selectivity in a study performed in N18TG2 cells. This compound exerted agonism through
Gαi3, while being an inverse agonist at Gαi1 and Gαi2 [112]. As previously observed for AEA, mAEA
exhibits a preference toward cAMP inhibition, compared to pERK1/2 [35].
More recently, the endocannabinoid and endovanilloid ligand, N-arachidonoyldopamine (NADA,
Figure 4) has been reported to exhibit biased agonism at CB1 [113]. Redmond and colleagues
demonstrated that this ligand exerts a unique CB1 signaling profile, showing significant bias in
activating Gαq-mediated responses. This effect seems to occur at high concentrations and in a cell- and
tissue-dependent manner.
Besides the aforementioned eicosanoids, a totally different endogenous chemical structure has
also been reported to act at CB1 in a biased way. This is the case of the steroid hormone pregnenolone
(Figure 5), which acts as a CB1 negative allosteric modulator of ∆9-tetrahydrocannabinol (∆9-THC,
Figure 6). This endogenous molecule has been reported to elicit biased responses, inhibiting pERK1/2
signaling while not modifying cAMP signaling [48].
The data collected thus far is not enough to determine the molecular basis of CB1 activation of
specific signaling pathways by endocannabinoids. Therefore, further studies extending structural
diversity among these lipids are clearly needed. The use of a broader spectrum of functional assays and
cellular types may also help in understanding each ligand’s pharmacological profile under different
pathophysiological conditions.
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4.2. Phytocannabinoids
Thus far, very few phytogenic cannabinoids have been reported to elicit biased signaling responses.
The major bioactive constituent in Cannabis Sativa, (−)∆9-tetrahydrocannabinol (∆9-THC), has been
described to be biased toward β-arrestin1 recruitment at CB1. Laprairie et al. demonstrated that,
in STHdh cells, ∆9-THC exhibits signaling biases toward β-arrestin1, Gαq, and Gβγ, compared to
Gαi/o [17]. More recently, these authors demonstrated that this compound is able to preferentially
enhance the recruitment of β-arrestin1 and reduce cellular viability in an in vitro model of Huntington
disease [13].
Previous studies, conducted by Breivogel et al., reported the sensitivity of this psychoactive
phytocannabinoid to β-arrestin2 in vivo. ∆9-THC was able to produce better antinociception and
greater body temperature decreases in β-arrestin2 knock-out mice, compared to their homozygous
wild-type counterparts [28,39].
The non-psychotropic cannabinoid cannabidiol (CBD, Figure 6), has also been explored to
characterize its possible functional selectivity at CB1. The cannabinoid pharmacology of CBD is
still quite intriguing [114]. Different reports showed that it displays a low affinity for CB1 [115],
while i vitro studies demonstrated its CB1 antagonistic properties [116,117]. More recently, Laprairie
et al. repor e that CBD behaves as a CB1 negative allosteric modulator (NAM) of ∆9-THC and
2-AG [118]. In this context, two different investigations evaluated the potential CBD signaling bias at
CB1. On one hand, studies in STHdh cells showed that CBD administration only evoked significant
Gαs-mediated pCREB and, therefore, bias values could not be considered for this ligand. However,
the combination of ∆9-THC and CBD induced signaling biased toward Gαs, compared with Gαi/o,
while being biased toward Gαi/o, compared with β-arrestin1, Gαq, and Gβγ [13,17]. On the other
hand, Navarro et al. assessed CBD´s effects by using four different functional outcomes and observed
that this phytocannabinoid induces changes in the response of CB1 to different agonists in a biased
Int. J. Mol. Sci. 2019, 20, 1837 13 of 24
manner [119]. Moreover, they showed that CBD can also alter the signaling of ∆9-THC acting on
CB1-CB2 heteromers.
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The potential functional bias of a wider range of phytocannabinoids, including their acidic
metabolites, should be further explored in diverse cellular systems. This will aid in developing an
understanding of the structural relevance of the aliphatic moiety, the phenolic core, or the cyclohexenyl
ring for each pathway, guiding future drug design.
4.3. Synthetic Cannabinoids
Certain synthetic cannabinergic drugs have been identified as biased ligands at CB1. Even if not
many scaffolds have been discovered to exhibit functional selectivity at this receptor, the knowledge
gained recently has contributed to progress in this field.
4.3.1. Phytocannabinoid Synthetic Derivatives.
Synthetic cannabinoids, such as CP55,940 and HU210 (Figure 7), have been explored through
diverse functional outcomes in observing specific signaling trends. The (–)-1,1-dimethylheptyl analog
of 11-hydroxy-∆8-tetrahydrocannabinol, HU210, was shown to elicit a significant bias towards cAMP
inhibition (Gαi/o stimulation) over pERK1/2 activation [35]. This compound elicited similar maximal
stimulation of Gαo and Gαi in Sf9 cells [63] and displayed equipotent Gαi versus Gαs signaling [120,121].
Moreover, Lauckner et al. showed that, in CB1-HEK293 cells, this compound did not increase calcium
release through a Gαq pathway, thus preferring Gαi signal transduction [22].
The widely-used CB1/CB2 agonist CP55,940 [122] also exhibited functional selectivity under
specific cellular conditions. Like HU210, CP55940 exhibited a preference for cAMP inhibition,
compared to pERK1/2, in CB1-HEK293 cells [35]. However, in contrast to the previous synthetic
cannabinoid, CP55,940 favored coupling to Gαi versus Gαs [120,121]. Moreover, Laprairie and
coworkers demonstrated that, in STHdh cells, CP55,940 induced signaling biased toward Gαs and
β-arrestin1 compared to Gαi/o [17].
Despite these findings, CP55,940 is usually considered to be an unbiased CB1 full agonist [123].
Divergences among assays may originate from intrinsic properties of the receptor, as well as the
functional outcome or cell type/tissue used for the evaluation.
4.3.2. Indoles
Diverse indole chemotypes, including the aminoalkylindole WIN55,212-2, the indole-2-carboxamide
ORG27569, and the indole quinulidinone PNR-4-20, have been reported to signal through CB1 in a
biased manner.
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The potent cannabinoid agonist WIN55,212-2 has been widely investigated using diverse functional
outcomes and exploring different signaling pathways. For instance, Glass and Northup observed that,
in membranes of CB1 expressing Sf9 cells, WIN55,212-2 elicited maximal Gαi activation, whereas it
only partially stimulated Gαo [63]. Studies from Lauckner et al. revealed that, at high concentrations,
this aminoalkylindole increased the release of intracellular calcium in CB1-HEK293 cells through
stimulation of the Gαq pathway. Therefore, these authors suggested that WIN55,212-2 is able to
stabilize CB1 receptors into a conformation that enables Gαq signaling, consequently shifting the
G-protein specificity [22]. Moreover, it was reported that WIN55,212-2 exerts equipotent Gαi and Gαs
signaling [120,124]. It is also interesting to remark that co-immunoprecipitation studies of activated
G-proteins in N18TG2 cells demonstrated that WIN55,212-2 behaved as a full agonist for the Gαi
subtypes Gα1, Gα2, and Gα3 [112]. In agreement with previous studies, Laprairie et al. observed that it
activates Gαq, Gαi and Gβγ [17]. Furthermore, the arrestin pathway has been extensively investigated
by Delgado-Peraza et al. [14]. These authors demonstrated that this compound was able to induce
prolonged activation of pERK1/2 in the mutant receptor (described in previous sections) which is
exclusively mediated by β-arrestin1. WIN55,212-2 was able to recruit β-arrestin1 more efficiently than
β-arrestin2, being therefore biased towards β-arrestin1.
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In 2005, the indole-2-carboxamide ORG27569 was described as the first CB1 allosteric
modulator [75,125]. It behaves as a positive allosteric enhancer of agonist binding; however,
it is functionally considered a negative allosteric modulator (NAM). Additional studies exhibited
controversial pharmacological data for ORG27569, revealing that the allosteric effects of ORG27569 at
CB1 might be pathway-specific and time-dependent [35,126]. These results suggest a more complex
process than the allosteric profile initially proposed.
In this context, experiments in CB1-HEK293 cells revealed that ORG27569 produces an increase
in phosphorylation of ERK1/2 that is not abrogated upon PTX treatment. This study indicates
that the observed signaling is not G-protein mediated [127]. Moreover, the role of β-arrestins in
G-protein-independent ORG27569 signaling was assessed using siRNA co-transfection, demonstrating
that β-arrestin1 mediates the ERK1/2 phosphorylation stimulated by this molecule [127]. However,
inverse agonism of ERK signaling by ORG27569 has also been reported [128].
This indole-2-carboxamide was the first biased allosteric modulator described [35,127,129],
opening new avenues for the development of subtype- and pathway-selective CB1 therapeutics.
Despite the promising signaling mechanism of these types of ligands, their pharmacological profiling
is especially challenging and further in vivo assays are needed to demonstrate the therapeutic outcome
of the complex biased signaling produced by ORG27569 at the CB1 receptor.
Prather et al. have recently reported the CB1 ligand bias profile of specific indole
quinulidinones [123]. This chemotype was previously identified by the same authors, who developed
several potent and efficacious CB1 agonists [130,131]. The indole quinulidinone PNR-4-20 (Figure 7)
was shown to elicit robust G-protein-dependent signaling, with transduction ratios comparable to
non-biased CB1 agonists [123]. However, in contrast to non-biased ligands, this compound is not able to
recruitβ-arrestin2. Due to this reduced arrestin recruitment, upon chronic exposure of cells to PNR-4-20,
significantly lower desensitization and down-regulation of CB1 receptors was detected when related
to a similar treatment with non-biased molecules. The indole quinulidinone derivative PNR-4-02 (an
analogue of PNR-4-20, in which the fluorine is replaced by a chlorine group) exhibited a similar CB1
bias profile, displaying efficacy for coupling CB1 to G-protein-dependent, β-arrestin2-independent
signaling pathways [123]. Ligands with this CB1 functionally-selective profile may offer the advantage
of producing less severe adverse effects, even upon chronic treatment.
4.3.3. Biphenylureas
The pyrrodinyl biphenylurea scaffold, PSNCBAM1 (Figure 7), was discovered as an allosteric
modulator of CB1 by Horswill et al. over a decade ago [132]. Follow-up structural studies
allowed for the identification of pharmacophoric moieties leading to the allosteric properties of
this chemotype. For instance, substitution of the chloro- group with a cyano- group generated
analogues with a similar pharmacological profile [133]. Further studies, by Kendall et al., enabled the
development of the pyrimidinyl biphenylureas LDK1288 and LDK1284 (Figure 7) as novel promising
lead molecules. Replacement of the pyridine moiety of PSNCBAM1 with a pyrimidine core led to novel
CB1 positive allosteric modulators that exhibit a pathway-specific signal transduction [134]. These new
compounds positively modulate the binding of the CB1 orthosteric agonist CP55,940 while exhibiting
an antagonism of G-protein coupling. Remarkably, the pyrimidinyl biphenylureas demonstrated
ERK1/2 phosphorylation, mediated by β-arrestin1 [134,135]. Therefore, these allosteric modulators
may help stabilize a CB1 active conformation that binds to β-arrestin1, while precluding G-protein
coupling. Due to their unique pharmacological profile, this promising scaffold may provide a novel
anti-obesity approach, mediated through a CB1 biased allosteric mechanism.
Despite the discovery of the aforementioned CB1 biased ligands, this field is yet emerging and
further studies need to optimize the bias quantification methods. Relative signaling efficacies and
especially the presence of scaffolding proteins may differ in diverse tissues and cell types. This fact,
along with intrinsic receptor properties, should be consistently studied to be able to reliably classify the
signaling bias of CB1 ligands. In addition, the time points selected to measure cellular endpoints should
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be standardized to equally account for differences in ligand kinetics. In this context, further structure
activity relationship studies, over a wide range of cannabinoid scaffolds and using a consistent bias
quantification, will help to identify key structural features and may guide future drug design.
It is worth mentioning that CB1 allosteric modulators may influence ligand bias by affecting
the conformation of the active state of a given receptor. They could promote an alternative active
conformation that prevents G-protein coupling while promoting β-arrestin recruitment, or vice
versa. In this context, as previously mentioned, biased allosterism is now emerging at CB1 and
should be further explored. In fact, the biased signaling of allosteric modulators may offer unique
therapeutic strategies, conferring selective fine-tuning of CB1-impacted pathways and, thus, reducing
the undesirable effects associated with orthosteric ligands.
Moreover, ligand bias can be influenced by receptor oligomerization in specific cells or tissues.
For instance, CB1-dependent Gαq signaling has been reported to occur through CB1-D2 (type 2
dopamine receptor) dimerization [136].
In addition to the numerous experimental challenges already mentioned, the actual goal of
studying CB1 ligand bias is to identify the correlation of specific signaling cascades and effector proteins
with behavioral and physiopathological results in vivo. This knowledge will aid the development of
therapeutically-optimized strategies, targeting pathways affected by particular conditions or symptoms.
5. Conclusions
This article aims to provide a comprehensive perspective of the structural knowledge gained
so far in the CB1 biased agonism field. Differential activation at the CB1 receptor may offer
fine-tuned therapeutic strategies for targeting specific symptoms or pathologies. Therefore, a molecular
understanding of the structural features that trigger and accompany the activation of each independent
pathway, in a biased manner, may provide further insights to move CB1 biased ligands towards
the clinic.
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Abbreviations
CB1 Cannabinoid receptor type 1
THC Tetrahydrocannabinol
CBD Cannabidiol
pERK1/2 Phosphorylation of extracellular signal-regulated kinase 1/2
AEA Anandamide
2-AG 2-Arachidonoylglycerol




MAPK Mitogen-Activated Protein Kinases
GIRK G-protein-coupled inwardly rectifying potassium channels
GRK G-protein-coupled Receptor Kinase
TMH Transmembrane helix
pERK Phosphorylated extracellular regulated kinases
GPCR G protein-coupled receptor
NMR Nuclear Magnetic Resonance
MS Mass Spectrometry
FRET Förster resonance energy transfer
EPR Electron paramagnetic resonance
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